MedPAC Analysis Of 'Low-Value' Medicare Treatments Spotlights Acthar

The Medicare Payment Advisory Commission’s annual 2018 report to Congress features the flip side of the recent value-based rhetoric – highlighting “low-value” Medicare purchases. The drug chosen to make that argument is Mallinckrodt’s HP Acthar Gel.